- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04985357
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
December 5, 2023 updated by: Travera Inc
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.
Study Overview
Status
Not yet recruiting
Conditions
- Carcinoma, Renal Cell
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Hepatocellular
- Carcinoma, Pancreatic
- Mesothelioma
- AML
- Cholangiocarcinoma
- Stage IV Lung Cancer
- Carcinoma, Neuroendocrine
- Stage IV Breast Cancer
- Carcinoma, Ductal
- Malignant Ascites
- Carcinoma Prostate
- Stage III Breast Cancer
- Carcinoma of the Appendix
- Carcinoma, Small Cell Lung
- Multiple Myeloma in Relapse
- Malignant Pleural Effusion
- Carcinoma Cervix
- Stage III Lung Cancer
- Carcinoma Breast
- Carcinoma of Unknown Primary
- Carcinoma of the Oral Cavity
- Carcinoma of the Oropharynx
- Carcinoma, Thymic
- Carcinoma of Lung
- Carcinoma, Ovarian
- Carcinoma Bladder
- Carcinoma of Esophagus
- Carcinoma of the Head and Neck
- Carcinoma of the Lip
- Carcinoma of the Skin
- Carcinoma of the Anus
- Carcinoma of the Larynx
- Carcinoma of the Penis
- Carcinoma of the Paranasal Sinus
- Carcinoma of the Vulva
Study Type
Observational
Enrollment (Estimated)
630
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mark Stevens, Ph.D.
- Phone Number: 6172999784
- Email: trv002@travera.com
Study Locations
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Recruiting
- Columbus Regional Research Institute, John B. Amos Cancer Center
-
Contact:
- Shelby Zikeli
- Phone Number: 706-321-0495
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
General population with cohort matched diagnoses.
Description
Inclusion Criteria:
- Sample collection or biopsy of tumor is clinically indicated as part of SOC
- Prior to preceding onto therapy for treatment
Exclusion Criteria:
- Unable to obtain sufficient sample
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Carcinoma-Associated Malignant Fluid
Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
Carcinoma Solid Tissue Specimen
Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
Multiple Myeloma
Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
Acute myelogenous leukemia (AML)
Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
Triple Negative Breast Cancer (TNBC)
Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
Peripheral Blood Cell Immune Competency
Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall response (BOR)
Time Frame: up to 24 months
|
The best overall response to therapy over 24 months will be captured for correlation with test outcomes.
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Stevens, Ph.D., Travera Inc
- Principal Investigator: Robert Kimmerling, Ph.D., Travera Inc
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
May 1, 2028
Study Completion (Estimated)
May 1, 2030
Study Registration Dates
First Submitted
July 15, 2021
First Submitted That Met QC Criteria
July 28, 2021
First Posted (Actual)
August 2, 2021
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Hematologic Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Pleural Diseases
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Breast Diseases
- Liver Diseases
- Prostatic Diseases
- Hemorrhagic Disorders
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Intestinal Diseases
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Liver Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Esophageal Diseases
- Neoplasms, Plasma Cell
- Colorectal Neoplasms
- Neoplasms, Complex and Mixed
- Neuroendocrine Tumors
- Vulvar Diseases
- Adenoma
- Ovarian Neoplasms
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Rectal Neoplasms
- Anus Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Thymus Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Carcinoma, Renal Cell
- Breast Neoplasms
- Prostatic Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Multiple Myeloma
- Carcinoma, Hepatocellular
- Thymoma
- Urinary Bladder Neoplasms
- Small Cell Lung Carcinoma
- Ascites
- Carcinoma, Ovarian Epithelial
- Vulvar Neoplasms
- Cholangiocarcinoma
- Esophageal Neoplasms
- Carcinoma, Neuroendocrine
- Carcinoma, Small Cell
- Mesothelioma
- Anus Neoplasms
- Pleural Effusion, Malignant
- Pleural Effusion
- Carcinoma, Ductal
Other Study ID Numbers
- TRV-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany